Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GRN | P28799 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425707 | 1.00 | LMNA (1.00) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL4119437 | 0.86 | LMNA (0.75) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL30175326 | 0.86 | LMNA (0.75) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL3503653 | 0.86 | LMNA (0.75) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL31005017 | 0.86 | LMNA (0.75) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| Hydrochloric Acid SCHEMBL5012059 | 0.84 | LMNA (0.73) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL12664231 | 0.82 | LMNA (0.69) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL63835 | 0.82 | LMNA (0.69) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL5437049 | 0.82 | KMT2A (1.00) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL27777451 | 0.82 | LMNA (0.69) | LMNAKMT2AKDM4EALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4665331-A1 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024173219-A1 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| EP-1196397-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000073283-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885KMT2A 1493/4885KDM4E 1198/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885KMT2A 1493/4885KDM4E 1198/4885 |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | LMNA 4384/4885KMT2A 2004/4885KDM4E 3864/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885KMT2A 1493/4885KDM4E 1198/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | LMNA 1845/4885KMT2A 2234/4885KDM4E 2800/4885 |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | LMNA 681/4885KMT2A 2682/4885KDM4E 3156/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | LMNA 3454/4885KMT2A 3282/4885KDM4E 4059/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | LMNA 1845/4885KMT2A 2234/4885KDM4E 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.